RecruitingPhase 1NCT05391490

Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies

Sponsor

University College, London

Enrollment

12 participants

Start Date

Feb 6, 2023

Study Type

INTERVENTIONAL

Conditions

Blood Cancer

Summary

KCAT19 is a single-centre, non-randomised, open-label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age 16-65 years) with high risk, relapsed/refractory (r/r) B cell malignancies.

Eligibility

Min Age: 16 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying KCAT19 T cells for people with blood cancer. The study is currently recruiting participants at 1 location. People eligible for this study include aged 16 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.